Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels

Fertility and Sterility

Volumn 95, Issue 7, 2011, Pages 2369-2372

  Buyuk, Erkan ^a   Seifer, David B ^b   Younger, Joshua ^a   Grazi, Richard V ^b   Lieman, Harry ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Anti M llerian hormone; ART; diminished ovarian reserve; elevated FSH levels; M llerian inhibiting substance; ovarian response

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; ASSISTED REPRODUCTIVE TECHNOLOGY; CONTROLLED STUDY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE; OVARY FUNCTION; OVARY RESPONSE; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; WOMEN'S HEALTH;

ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; FOLLICULAR PHASE; HUMANS; INFERTILITY, FEMALE; NEW YORK; OOCYTE RETRIEVAL; OVULATION; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 79956351551     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2011.03.071     Document Type: Article

References (19)

1. Society for Assisted Reproductive Technology. IVF Success rates, National Data Summary. http://www.sart.org/frame/detail.aspx?id=3893.
2. Centers for Disease Control and Prevention. Outline for a national action plan for the prevention, detection and management of infertility. May 7, 2010. http://www.cdc.gov/art/PDF/NationalActionPlan.pdf.
3. M.E. Coccia, and F. Rizzello Ovarian reserve Ann N Y Acad Sci 1127 2008 27 30 (Pubitemid 351563104)
4. E. Papaleo, L. De Santis, F. Fusi, N. Doldi, C. Brigante, and G. Marelli Natural cycle as first approach in aged patients with elevated follicle-stimulating hormone undergoing intracytoplasmic sperm injection: a pilot study Gynecol Endocrinol 22 2006 351 354 (Pubitemid 44180260)
5. A.K. Sullivan, M. Marcus, M.P. Epstein, E.G. Allen, A.E. Anido, and J.J. Paquin Association of FMR1 repeat size with ovarian dysfunction Hum Reprod 20 2005 402 412 (Pubitemid 40277608)
6. L.E. Bath, W.H. Wallace, M.P. Shaw, C. Fitzpatrick, and R.A. Anderson Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound Hum Reprod 18 2003 2368 2374 (Pubitemid 37427819)
7. A. Iwase, W. Hirokawa, M. Goto, S. Takikawa, Y. Nagatomo, and T. Nakahara Serum anti-Mullerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve Fertil Steril 94 2010 2846 2849
8. R.R. Behringer, M.J. Finegold, and R.L. Cate Mullerian-inhibiting substance function during mammalian sexual development Cell 79 1994 415 425
9. B. Vigier, J.Y. Picard, D. Tran, L. Legeai, and N. Josso Production of anti-Mullerian hormone: another homology between Sertoli and granulosa cells Endocrinology 114 1984 1315 1320 (Pubitemid 14134383)
10. J.A. Visser, F.H. de Jong, J.S. Laven, and A.P. Themmen Anti-Mullerian hormone: a new marker for ovarian function Reproduction 131 2006 1 9 (Pubitemid 43230697)
11. S.Y. Shin, J.R. Lee, G.W. Noh, H.J. Kim, W.J. Kang, and S.H. Kim Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status J Korean Med Sci 23 2008 104 110
12. D.B. Seifer, and D.T. Maclaughlin Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance Fertil Steril 88 2007 539 546 (Pubitemid 47368260)
13. A. Hazout, P. Bouchard, D.B. Seifer, P. Aussage, A.M. Junca, and P. Cohen-Bacrie Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol Fertil Steril 82 2004 1323 1329 (Pubitemid 39469455)
14. D.B. Seifer, D.T. MacLaughlin, B.P. Christian, B. Feng, and R.M. Shelden Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles Fertil Steril 77 2002 468 471 (Pubitemid 34177199)
15. A. La Marca, S.M. Nelson, G. Sighinolfi, M. Manno, E. Baraldi, and L. Roli Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction Reprod Biomed Online 22 2011 341 349
16. D.B. Seifer, V.L. Baker, and B. Leader Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States Fertil Steril 95 2011 747 750
17. B. Kumbak, E. Oral, S. Kahraman, G. Karlikaya, and H. Karagozoglu Young patients with diminished ovarian reserve undergoing assisted reproductive treatments: a preliminary report Reprod Biomed Online 11 2005 294 299 (Pubitemid 41269567)
18. A. La Marca, S. Malmusi, S. Giulini, L.F. Tamaro, R. Orvieto, and P. Levratti Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation Hum Reprod 19 2004 2738 2741 (Pubitemid 40028941)
19. N. Gleicher, A. Weghofer, and D.H. Barad Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve Fertil Steril 94 2010 2824 2827